MK-677 (Ibutamoren) Pricing: April 2026

MK-677 (Ibutamoren) is an oral, non-peptide ghrelin receptor agonist that stimulates growth hormone release. Despite its popularity in the peptide wellness community, it's technically a small molecule, not a peptide — a distinction that matters for how it's accessed.

Mechanism: MK-677 activates the GHS-R1a receptor, sustaining the GH–IGF-1 axis with a ~24-hour half-life (enabling once-daily dosing). Clinical studies show GH secretion increases up to ~97% and IGF-1 levels return to those of young adults. Bedtime dosing is preferred — a 25mg dose at bedtime increased REM sleep 20% in young subjects and 50% in older subjects.

Common dosages: 10 mg (modest response), 12.5 mg (starting dose), or 25 mg daily (most common therapeutic dose). Typical cycles are 8–16 weeks.

Forms: Oral capsules (10/12.5/15/25mg) are most common, with liquid solution (25 mg/mL) and research powder also available. No injectable form.

Regulatory status (April 2026): NOT FDA-approved. NOT a controlled substance. WADA-banned (S2 category). The February 2026 RFK Jr. peptide reclassification did NOT include MK-677 because it's not a peptide. Products sold as dietary supplements are considered adulterated — the FDA issued recalls in September 2025 (iKids-Growth) and March 2026 (Agebox). The July 2026 FDA Pharmacy Compounding Advisory Committee meeting may consider 503A bulk list inclusion.

Access reality: Unlike peptides like BPC-157 or GHK-Cu, MK-677 is NOT widely prescribed by mainstream telehealth platforms (Maximus, Hone Health, Strut, AgelessRx). Most real-world access is through research chemical vendors labeled "not for human consumption." Insurance does not cover MK-677.